“Efficacy and Safety Outcomes from the MATISSE Phase 3 Trial of Maternal Bivalent RSVpreF Vaccination Among Pregnant Women Vaccinated at 32 to 36 Weeks of Gestation”. Swiss Medical Weekly, vol. 156, no. 1, Jan. 2026, p. 4711, https://doi.org/10.57187/4711.